SynBioBeta Speaker

Sue Siegel

Align Technology

Board Director & Chairman

Sue Siegel is a seasoned board director, former CEO, and venture capitalist with a rare blend of governance expertise, commercial acumen, operational prowess, and innovation leadership across life sciences, healthcare, and technology. For more than 25 years, she has helped boards anticipate disruption, strengthen oversight, and unlock long-term value.

She currently serves on the boards of Align Technology, Illumina, and KFF (formerly Kaiser Family Foundation), and is Chairman of the Board of The Engine, built by MIT. Over her career, she has served on more than 20 public, private, and nonprofit boards with extensive Audit, Compensation, Nominating & Governance, Technology, Investment, and Special Committee experience—including multiple chair roles. Recognized on the NACD Directorship 100 in 2023 and 2024, she is widely regarded as an inspirational, pragmatic, and forward-thinking leader who blends strategic foresight with disciplined governance.

Her executive career includes serving as Chief Innovation Officer at GE, CEO of GE Ventures & Licensing, and CEO of Healthymagination, advancing investments and partnerships at the intersection of healthcare and technology. Previously, she was a General Partner at Mohr Davidow Ventures, leading life sciences and precision health investments, and President & Board Director of Affymetrix, where she led the company from a pre-revenue startup to a multi-billion-dollar, NASDAQ-listed global genomics leader—helping shape the field’s early growth and address emerging bioethical issues.

In public service, Sue has served on President Obama’s Precision Medicine Initiative Working Group, catalyzing the All of Us research program; was a founding board member of the National Center for Advancing Translational Sciences; and acted as a White House Fellows selection judge under multiple administrations. She also co-chairs Stanford Medicine’s Board of Fellows and serves on the Innovation Growth Board of Mass General Brigham.

Her leadership has been recognized by Fortune’s “34 Leaders Who Are Changing Health Care,”the Silicon Valley Business Journal’s “100 Most Influential Women in Silicon Valley,” Fierce Biotech’s “Top 10 Women in Medical Devices,” and the Global Corporate Venture Lifetime Achievement Award. An Aspen Institute Henry Crown Fellow, she is featured in the bestselling book Multipliers: How the Best Leaders Make Everyone Smarter and serves on the faculty of MIT Sloan School of Management.

SynBioBeta 2026 Tickets are Live

Confirmed Speakers

Sessions Featuring

Sue

This Year

Main Stage Panel

9:00 AM

-

9:30 AM

The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier

Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows. 

Purchase Pass

Main Stage Panel

9:00 AM

-

9:30 AM

The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier

Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows. 

Purchase Pass

TBD

Session lineup still growing

Purchase Pass

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Purchase Pass

Featuring

Speaker Coming Soon

Previous Speakers Include